摘要
[目的]观察和研究抗感染活性骨(anti-infective reconstituted bone xenograft,ARBX)I期植骨治疗慢性血源性骨髓炎的疗效。[方法]在获得总后卫生部军内临床试用研究许可的基础上,自2001年9月起将ARBX用于临床治疗慢性血源性骨髓炎24例,对其中17例获得12个月以上系统随访的患者进行疗效分析。[结果]17例中除1例骨髓炎未能治愈,1例骨髓炎治愈后复发,1例骨髓炎合并大段骨缺损在术后发生骨不连外;其余14例骨髓炎均获得完全治愈,病变部位均获得确实骨修复,无骨髓炎复发。本组慢性骨髓炎总治愈率为82.4%,远高于传统治疗方法。[结论]ARBX具有高效诱导成骨活性和强效抗感染能力,能I期植骨有效治疗慢性血源性骨髓炎。
[Objective]To study the effect of anti-infective reconstituted hone xenograft （ARBX） on treating chronic hematogenous osteomyelitis as one-stage grafting.[Method] ARBX was used to treat 24 cases of chronic hematogenous osteo-myelitis as one - stage grafting after debridement since September of 2001, 17 cases of which were followed up for an average pe- riod of 34 months （range, 12 to 79 months） . [ Result] Except 1 case failed to cure, and 1 resulted in recurrence of infection, and 1 with large segmental bone defect nonunion post - operatively, other 14 cases were cured, the cure rate was 82.4% which was better than traditional therapy. [Conclusion] ARBX has high osteoinductive activity and enhanced anti-infective capability, which enables it to be used as primary grafting to treat chronic hematogenous osteomyclitis.
出处
《中国矫形外科杂志》
CAS
CSCD
北大核心
2008年第23期1768-1770,共3页
Orthopedic Journal of China
基金
国家科技支撑计划课题(NO.2006BAI16B02)
全军医药卫生科研基金“十一.五”指令性课题(NO.06Z057)资助
关键词
血源性
骨髓炎
骨移植
抗生素
hematogenous
osteomyelitis
bone transplantation
antibiotic
